Exosomes Market Size & Share, by Product & Services (Kits, Reagents, Instrument); Indication (Cancer, Infectious Diseases); Work Flow (Isolation Methods, Downstream Analysis); Application (Diagnostic, Therapeutic); Manufacturing Services (Stem Cell, Dendritic Cell-Derived); End-User (Academic & Research Institutes, Hospital & Clinical Testing Laboratories, Pharmaceutical & Biotechnology Companies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5373
  • Published Date: Nov 14, 2023
  • Report Format: PDF, PPT

Companies Dominating the Exosomes Landscape

top-features-companies
    • Thermo Fisher Scientific, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • System Biosciences
    • Lonza Group Ltd
    • Danaher Corporation
    • Bio-Techne Corporation
    • RoosterBio, Inc.
    • Global Stem Cells Group
    • QIAGEN N.V.
    • Miltenyi Biotech Technology & Trading Co., Ltd.
    • Clara Biotech

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • February 2022: Bio-Techne Corporation (NASDAQ: TECH) today announced an agreement with Thermo Fisher Scientific to exclusively complete development of and commercialize the ExoTRU kidney transplant rejection test developed by Exosome Diagnostics, a Bio-Techne brand. ExoTRU is a non-invasive multigene urine based liquid biopsy assay that provides critical allograft health information to assist clinician decision making in managing kidney transplant patients and optimizing patient care. The assay has the potential to discriminate between T-cell mediated rejection (TCMR) and antibody mediated rejection (ABMR), which is critical to improving patient management and outcomes.  ExoTRU was developed in collaboration with the Azzi Laboratory at the Transplantation Research Center at Brigham and Women's Hospital, Harvard Medical School.
  • November 2021: Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, announced today the acquisition of an exosome manufacturing facility located in Lexington, Massachusetts (US) from Codiak BioSciences, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics. Codiak will retain its pipeline of therapeutic candidates as well as its exosome engineering and drug-loading technologies. Codiak will receive as part of the deal approximately $65 million of cGMP manufacturing services in kind. Lonza will gain worldwide access and sub-licensable rights to Codiak's high-throughput perfusion-based cGMP process for exosome manufacturing.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5373
  • Published Date: Nov 14, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing prevalence of chronic diseases and increasing funds for life sciences R&D are the major factors driving the growth of the exosomes market.

The market size of exosomes is anticipated to attain a CAGR of 16% over the forecast period, i.e., 2024-2036.

The major players in the market are System Biosciences, Lonza Group Ltd, Danaher Corporation, Bio-Techne Corporation, RoosterBio, Inc., Global Stem Cells Group, QIAGEN N.V., Miltenyi Biotech Technology & Trading Co., Ltd., and others.

The cancer segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying